Practical Aspects of Radioligand Therapy in the Clinic VL

Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer - Neal Shore

Details
Neal Shore joins Alicia Morgans during APCCC 2022 to discuss sequencing strategies to implement lutetium-617 for patients with metastatic castration-resistant prostate cancer (mCRPC). Drs. Shore and Morgans consider the many treatment options now available as Dr. Shore emphasizes that monotherapy should no longer be an option. Finally, important concerns about bone health and its impact on treatme...

Imaging and PET Analysis as a Prognostic Tool for Lu-PSMA-617 Treatment in Patients with mCRPC - Phillip H. Kuo

Details
Phillip Kuo joins Alicia Morgans to discuss recent findings in a VISION sub-study. Dr. Kuo explains how this post-hoc exploratory analysis of the PSMA PET scans that were done for the VISION trial resulted in a better understanding of which patients are likely to respond better to treatment with lutetium-PSMA-617. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of Medical Imaging, Medicine and B...

Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans in a discussion on implementation strategies for integrating Lutetium-177 (177Lu-PSMA-617) into clinical practices and the challenges that we're facing with availability issues. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research, New Orleans, Louisiana Alici...

Methods for Preparation and Administration of Pluvicto™ (177Lu-PSMA-617) - Kendra Harris

Details
From the Tulane Cancer Center, Kendra Harris, a radiation oncologist explains the process of preparing for administering a dose of Pluvicto™ (177Lu-PSMA-617). Lutetium-177 received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associat...

Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris

Details
From the Tulane Cancer Center, Kendra Harris, Chair of Radiation Oncology explains the process of preparing for treatment of Pluvicto™ (177Lu-PSMA-617). Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate...

Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo

Details
From the Tulane Cancer Center, Kendra Harris Chair of Radiation Oncology demonstrates the process of administering a dose of Pluvicto™ (177Lu-PSMA-617). Phillip Koo meets with the patient in a brief post-dose administration discussion. Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer...

Integration of Pluvicto™ (177Lu-PSMA-617) in Clinical Practice - Oliver Sartor and Kendra Harris

Details
Drs Oliver Sartor and Kendra Harris join Phillip Koo to discuss the clinical implications and integration of Pluvicto™ into clinical practice and offer guidance to clinicians looking to implement this therapy in their clinics. Pluvicto™ (177Lu-PSMA-617) is the first FDA-approved targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: A. Olive...

Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris

Details
Chair of Radiation Oncology at Tulane University Cancer Center, Kendra Harris joins Phillip Koo to discuss radiation safety in regards to the recent approval of Pluvicto™, the first targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate Professor, Tulane Cancer Center, Tulane Unive...

Building a Sustainable Radioligand Treatment Clinic – Charlotte Manogue

Details
Phillip Koo and Charlotte Manogue, GU Program Manager at Tulane Cancer Center discuss aspects of transitioning from a clinical trial model into a sustainable treatment program for 177Lu-PSMA-617 for advanced prostate cancer at Tulane Cancer Center in New Orleans, Louisiana. Biographies: Charlotte Manogue, MPH, Senior Clinical Research Coordinator, Tulane Cancer Center, Tulane University School of...

Patient Management and Operationalizing Lutetium-177–PSMA-617 for Metastatic Castration Resistant Prostate Cancer in the Clinic – Charlotte Manogue and Oliver Sartor

Details
Oliver Sartor, Medical Director of the Tulane Cancer Center and co-PI on the Phase III VISION trial, and Charlotte Manogue, Senior Clinical Research Coordinator at Tulane Cancer Center join Phillip Koo in a discussion on identifying the patients and managing the patient care process for treatment with radioligand therapy in the clinic. Biographies: Oliver Sartor, MD, CE and Bernadine Laborde Profe...
email news signup